Cassiopea S.p.A. / Key word(s): Delisting Cassiopea SpA announces approval of delisting of its shares on SIX Swiss Exchange 25.02.2022 / 07:00 Lainate, Italy - February 25, 2022: Cassiopea S.p.A. (SIX: SKIN), ('Cassiopea'), a specialty pharmaceutical company developing and preparing to commercialize prescription drugs with novel mechanisms of action (MOA) to address long-standing essential dermatological conditions, today announced that SIX Exchange Regulation has approved the delisting of its shares from the SIX Swiss Exchange with the last day of trading on March 4, 2022,...
Cassiopea S.p.A. / Schlagwort(e): Delisting Cassiopea SpA gibt Genehmigung zur Dekotierung ihrer Aktien an der SIX Swiss Exchange bekannt 25.02.2022 / 07:00 Lainate, Italien - 25. Februar 2022: Cassiopea S.p.A. (SIX: SKIN) («Cassiopea»), ein Spezialpharma-Unternehmen, das verschreibungspflichtige Medikamente mit neuartigen Wirkmechanismen zur Behandlung langjähriger und wesentlicher dermatologischer Erkrankungen entwickelt und deren Vermarktung vorbereitet, gab heute bekannt, dass die SIX Exchange Regulation die Dekotierung seiner Aktien von der SIX Swiss Exchange mit dem l...
Cassiopea S.p.A. / Key word(s): Miscellaneous Cassiopea SpA announces preparing delisting of shares on SIX Swiss Exchange 20.01.2022 / 07:00 Lainate, Italy - January 20, 2022: Cassiopea SpA (SIX: SKIN), a specialty pharmaceutical company developing and preparing to commercialize prescription drugs with novel mechanisms of action (MOA) to address long-standing essential dermatological conditions, today announced that it has been asked by Cosmo, its almost 100% shareholder, to proceed to delist the shares from the SIX Swiss Exchange as soon as possible, and to start the proce...
Cassiopea S.p.A. / Schlagwort(e): Sonstiges SpA kündigt die Vorbereitung der Dekotierung der Aktien an der SIX Swiss Exchange an 20.01.2022 / 07:00 Lainate, Italien - 20. Januar 2020: Cassiopea SpA (SIX: SKIN), ein Spezialpharma-Unternehmen, das verschreibungspflichtige Medikamente mit neuartigen Wirkmechanismen zur Behandlung langjähriger und wesentlicher dermatologischer Erkrankungen entwickelt und deren Vermarktung vorbereitet, gab heute bekannt, dass es von Cosmo, seinem fast 100-prozentigen Anteilseigner, gebeten wurde, die Dekotierung der Aktien an der SIX Swiss Excha...
CASSIOPEA SPA (CH), a company active in the Pharmaceuticals industry, has received a double requalification by the independent financial analyst theScreener. Its fundamental valuation is now 4 out of 4 stars while its market behaviour can be considered as defensive. theScreener believes that the gain of a star(s) and an improvement in the market risk perception allows upgrading the general evaluation to Slightly Positive. As of the analysis date December 10, 2021, the closing price was CHF 38.30...
EQS Group-News: Cassiopea S.p.A. / Schlagwort(e): Produkteinführung Cassiopea SpA gibt die Markteinführung von Winlevi(R) (Clascoterone Crème 1%) in den USA bekannt 03.11.2021 / 07:00 Lainate, Italien, 3. November 2021: Cassiopea SpA (SIX: SKIN), ein Spezialpharma-Unternehmen, das verschreibungspflichtige Medikamente mit neuartigen Wirkmechanismen zur Behandlung langjähriger und wesentlicher dermatologischer Erkrankungen entwickelt und deren Vermarktung vorbereitet, gab heute die Markteinführung von Winlevi(R) (Clascoterone Crème 1%) per 1. November 2021 in den USA durch Pa...
EQS Group-News: Cassiopea S.p.A. / Key word(s): Product Launch Cassiopea SpA announces the US launch of Winlevi(R) (clascoterone cream 1%) 03.11.2021 / 07:00 Lainate, Italy, November 3, 2021: Cassiopea SpA (SIX: SKIN), a specialty pharmaceutical company developing and preparing to commercialize prescription drugs with novel mechanisms of action (MOA) to address long-standing essential dermatological conditions, today announced the US launch effective November 1, 2021, of Winlevi(R) (clascoterone cream 1%) by its partner, Sun Pharmaceutical Industries Ltd. Winlevi(R) is the ...
A director at Cassiopea Spa sold 2,971 shares at 32.000CHF and the significance rating of the trade was 57/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly sh...
Full Article at IIR has reaffirmed its Recommended rating for PIA after undertaking a review post the appointment of a new Portfolio Manager, Harding Loevner. The full report can be found on the IIR website. On 26 July 2021, Pengana International Equities Limited (PIA) announced a fully franked dividend of 1.35 cents per share for the June quarter. This represents an 8% increase on the March quarter dividend and takes the total dividends declared for FY21 of 5.1 cents per share, fully franked....
Ford Equity International Research Reports cover 60 countries with over 30,000 stocks traded on international exchanges. A proprietary quantitative system compares each company to its peers on proven measures of business value, growth characteristics, and investor behavior. Ford's three recommendation ratings buy, hold and sell, represent each stock’s return potential relative to its own country market.. The rating reports which are generated each week, include the fundamental details behind...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.